A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

• ClinicalTrials.gov Identifier: NCT00344305
• Recruitment Status: Completed
• First Posted: June 26, 2006
• Results First Posted: November 1, 2010
• Last Update Posted: July 24, 2017
• Sponsor: MedImmune LLC
• Information provided by (Responsible Party): MedImmune LLC

Study Description

Brief Summary:

Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to < 60 months of age, with 28-day shedding follow-up and 180-day safety follow-up.

Condition or disease	Intervention/treatment	Phase
Healthy	Biological: Trivalent influenza virus vaccine live, intranasal	Phase 2

Detailed Description:

This was a Phase 2, open-label, single-arm, multicenter study designed to evaluate vaccine virus shedding and safety of trivalent influenza virus vaccine live, intranasal in children 6 to < 60 months of age. Enrollment of approximately 200 participants was stratified by age, with 100 participants 6 to < 24 months of age (who reached their sixth month but not their second year birthday) and 100 participants 24 to < 60 months of age (who reached their second year but not their fifth year birthday). Baseline medical history data collection included the participants prior receipt of influenza vaccine or history of laboratory-confirmed influenza illness in the previous influenza season.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 200 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to Less Than 60 Months of Age
• Actual Study Start Date: May 1, 2006
• Actual Primary Completion Date: July 1, 2006
• Actual Study Completion Date: December 1, 2006

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort 1: Participants Between 6 to < 24 Months Age; Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).	Biological: Trivalent influenza virus vaccine live, intranasal; A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains.; Other Names: FluMist; Cold-adapted influenza virus vaccine, trivalent (CAIV-T); Live attenuated influenza virus (LAIV)
Experimental: Cohort 2: Participants Between 24 to < 60 Months Age; Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).	Biological: Trivalent influenza virus vaccine live, intranasal; A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains.; Other Names: FluMist; Cold-adapted influenza virus vaccine, trivalent (CAIV-T); Live attenuated influenza virus (LAIV)

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants Who Shed Any Vaccine Virus [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by polymerase chain reaction (PCR) based assays. Viral shedding (A/New Caledonia/20/99 [H1N1]; A/Wyoming/03/2003 [H3N2] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
2. Percentage of Participants Who Shed A/H1N1 Vaccine Virus [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 [H1N1]; A/Wyoming/03/2003 [H3N2] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
3. Percentage of Participants Who Shed A/H3N2 Vaccine Virus [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 [H1N1]; A/Wyoming/03/2003 [H3N2] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
4. Percentage of Participants Who Shed B Vaccine Virus [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 [H1N1]; A/Wyoming/03/2003 [H3N2] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

Secondary Outcome Measures :

1. Duration of Any Vaccine Virus Shedding [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   The number of days of shedding was summarized for all participants who shed any vaccine virus.
2. Duration of Confirmed A/H1N1 Vaccine Virus Shedding [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   The number of days of shedding was summarized for all participants who shed confirmed A/H1N1 strain virus.
3. Duration of Confirmed A/H3N2 Vaccine Virus Shedding [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   The number of days of shedding was summarized for all participants who shed confirmed A/H3N2 strain virus.
4. Duration of Confirmed B Vaccine Virus Shedding [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   The number of days of shedding was summarized for all participants who shed confirmed B strain virus.
5. Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   Quantitation of confirmed A/H1N1 shed vaccine virus was evaluated using the log transformed median tissue culture infectious dose (TCID50) per (/) millilitre (mL) for A/H1N1 vaccine strain and summarized for all participants who shed vaccine virus.
6. Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   Quantitation of confirmed A/H3N2 shed vaccine virus was evaluated using the log (TCID50)/mL for A/H3N2 vaccine strain and summarized for all participants who shed vaccine virus.
7. Quantitation of Confirmed B Shed Vaccine Virus on Any Day [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   Quantitation of confirmed B shed vaccine virus was evaluated using the log (TCID50)/mL for B vaccine strain and summarized for all participants who shed vaccine virus.
8. Number of Participants With Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the cold-adapted (ca) and temperature-sensitive (ts) phenotypes. Viruses were considered ts if their titer at 39 degrees Celsius (°C) was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
9. Number of Participants With Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
   The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 39°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
10. Number of Participants With Genotypic and Phenotypic Stability of B Shed Vaccine Virus [ Time Frame: Days 1-28 after study vaccination (up to Day 28) ]
    The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 37°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
11. Number of Participants With Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination [ Time Frame: Days 0-28 after vaccination (up to Day 28) ]
    REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
12. Number of Participants With Serious Adverse Events (SAEs) and Significant New Medical Conditions (SNMC) Through 180 Days Post Vaccination [ Time Frame: Days 0-180 after vaccination (up to 6.5 months) ]
    An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An SNMC is defined as a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. SNMCs included, but were not limited to, diabetes, asthma, autoimmune disease (lupus, rheumatoid arthritis), and neurological disease (epilepsy, autism).
13. Number of Participants With REs in Relation to Any Vaccine Virus Shedding [ Time Frame: Days 0-28 after study vaccination (up to Day 28) ]
    REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability.

Eligibility Criteria

• Ages Eligible for Study: 6 Months to 59 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Male or female, 6 months to less than 60 months of age (reached their 6th month but not yet reached their 5th year birthday) at the time of study vaccination
• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization obtained from the participants parent/legal representative
• Ability of the participants parent/legal representative to understand and comply with the requirements of the study
• Participants parent/legal representative available by telephone
• Ability to complete follow-up period of 180 days after study vaccination as required by the protocol

Exclusion Criteria:

• History of hypersensitivity to any component of trivalent influenza virus vaccine live, intranasal, including egg or egg products, monosodium glutamate, or porcine gelatin
• History of hypersensitivity to gentamicin
• History of Guillain-Barré syndrome
• Medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled), by parent/legal representative report or chart review, within the 42 days prior to study vaccination (i.e., children with recent persistent asthma were excluded); or history of severe persistent asthma according to the criteria described in the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report
• Acute febrile (greater than or equal to [>=] 100.0 degree Fahrenheit [°F] oral or equivalent) and/or clinically significant respiratory illness (e.g., cough or sore throat) within 72 hours prior to study vaccination
• Any known immunosuppressive condition or immune deficiency disease (including human immunodeficiency virus [HIV] infection), or ongoing receipt of any immunosuppressive therapy
• Household contact who was immunocompromised (participants were also to avoid close contact with immunocompromised individuals for at least 21 days after study vaccination)
• Use of aspirin or aspirin-containing products within the 30 days prior to study vaccination, or expected receipt through 180 days after study vaccination
• Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within the 14 days prior to study vaccination, or expected receipt through 28 days after study vaccination
• Use of any intranasal medication within the 14 days prior to study vaccination, or expected receipt through 28 days after study vaccination
• Administration of any live virus vaccine within the 30 days prior to study vaccination, or expected receipt through 30 days after study vaccination
• Administration of any inactivated (i.e., non-live) vaccine within the 14 days prior to study vaccination, or expected receipt through 14 days after study vaccination
• Receipt of any investigational agent within the 30 days prior to study vaccination, or expected receipt through 180 days after study vaccination (use of licensed agents for indications not listed in the package insert was permitted)
• Receipt of any blood product within the 90 days prior to study vaccination, or expected receipt through 28 days after study vaccination
• Family member or household contact who was an employee of the research center or otherwise involved with the conduct of the study
• Any condition that in the opinion of the investigator would have interfered with evaluation of the vaccine or interpretation of study results

Contacts and Locations

Locations

United States, Arkansas

Little Rock Allergy & Asthma Clinic, PA

Little Rock, Arkansas, United States, 72205

United States, Georgia

Pediatric and Adolescent Medicine, PA (PAMPA)

Marietta, Georgia, United States, 30062

United States, Kentucky

Kentucky Pediatrics/Adult Research

Bardstown, Kentucky, United States, 40004

United States, Louisiana

Benchmark Research

Metairie, Louisiana, United States, 70006

United States, New York

Health Sciences Research Center

Cortland, New York, United States, 13045

Health Sciences Research Center

Elmira, New York, United States, 14901

Regional Clinical Research Inc.

Endwell, New York, United States, 13760

United States, Oklahoma

Grand Prairie Pediatrics & Allergy Clinic

Oklahoma City, Oklahoma, United States, 73132

United States, Pennsylvania

Primary Physicians Research , Inc

Pittsburgh, Pennsylvania, United States, 15241

United States, Texas

Med-Pro Research Inc.

Houston, Texas, United States, 77004

Central Texas Health Research

New Braunfels, Texas, United States, 78130

Benchmark Research

San Angelo, Texas, United States, 76904

United States, Utah

Wee Care Pediatrics

Layton, Utah, United States, 84041

Utah Valley Pediatrics

Provo, Utah, United States, 84604

United States, Virginia

PI-Coor Clinical Research, LLC

Burke, Virginia, United States, 22015

Advanced Pediatrics

Vienna, Virginia, United States, 22180

Sponsors and Collaborators

MedImmune LLC

Investigators

• Study Director: Raburn Mallory, M.D.; MedImmune LLC

More Information

Publications of Results:

Mallory RM, Yi T, Ambrose CS. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Vaccine. 2011 Jun 10;29(26):4322-7. doi: 10.1016/j.vaccine.2011.04.022. Epub 2011 Apr 20.

• Responsible Party: MedImmune LLC
• ClinicalTrials.gov Identifier: NCT00344305
• Other Study ID Numbers: MI-CP129
• First Posted: June 26, 2006
• Results First Posted: November 1, 2010
• Last Update Posted: July 24, 2017
• Last Verified: July 2017

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MedImmune LLC:

children, FluMist, shedding,

Additional relevant MeSH terms:

Vaccines; Immunologic Factors; Physiological Effects of Drugs